RecruitingPhase 2

Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

United States70 participantsStarted 2019-09-03

Plain-language summary

We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients undergoing esophagectomy Exclusion Criteria: * Patients with more than mild pulmonary dysfunction * Patients with any neuromuscular disease that might compromise diaphragm function * Patients with abnormal liver or kidney function * Patients taking any immunosuppressant medication (including prednisone) or antifungal medications * History of tuberculosis * Weight loss of \>5% of body weight over previous 6 months * Pregnancy

What they're measuring

Prevention of ventilator-induced diaphragm dysfunction by JAK inhibition

Timeframe: 5-6 years

Trial details

NCT IDNCT03681275

SponsorStanford University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-11-30

Contact for this trial

Cheyenne A Clinical Research Coordinator, B.S, M.S

3107201689 csadeghi@stanford.edu

View on ClinicalTrials.gov More Diaphragm Injury trials